health biotech news today obesity drugs glp-1 New Pill Foundayo (Orforglipron) Gets FDA Approval for World Health Organization recommends GLP-1

- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539) FDA - Compounded Drug Products: Section 503A and 503B Pharmacies FDA Prescribing Information - semaglutide (weekly injection, chronic weight management) FDA Prescribing Information - tirzepatide (weekly injection, chronic weight management) Comparison sources Why GLP-1 Users Choose MeAgain Over Medication-Tracking Apps Like Shotsy 4.8 out of 5 from 23K App Store ratings with users repeatedly calling out the same shift: they do not just want a shot log

It's important to remember, however, that these benefits arise when GLP-1s are used under medical supervision as part of a comprehensive plan tailored to your individual needs

These programs dont help uninsured patients but are game-changers for those with commercial insurance that denies coverage

People who have not seen success with other weight loss medications or treatments

population will be obese by 2030, which is defined as abnormal or excessive fat accumulation that presents a risk to health by the World Health Organization

A 2024 study suggests injectable semaglutide leads to more weight loss in real-world settings